Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases

BACKGROUND: Orphan drug designations are a useful proxy to investigate trends in rare disease drug development. Drug developers must receive a designation before they are eligible for the economic incentives of the Orphan Drug Act in the United States. We created a database of all orphan drugs desig...

Descripción completa

Detalles Bibliográficos
Autores principales: Miller, Kathleen L., Fermaglich, Lewis J., Maynard, Janet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8191002/
https://www.ncbi.nlm.nih.gov/pubmed/34107994
http://dx.doi.org/10.1186/s13023-021-01901-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8191002/
https://www.ncbi.nlm.nih.gov/pubmed/34107994
http://dx.doi.org/10.1186/s13023-021-01901-6

Ejemplares similares